All In MedTech

Device Trial Radar · NCT05701488

SIRT With Tremelimumab and Durvalumab for Resectable HCC

A Phase 1 Neoadjuvant Trial of Selective Internal Yttrium-90 Radioembolization (SIRT) With Tremelimumab and Durvalumab (MEDI4736) for Resectable Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Actual

Start

Apr 21, 2023

Primary completion

Oct 1, 2027

Study completion Oct 1, 2027

Sponsor

Lead sponsor
Jiping Wang, MD, PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AstraZeneca; Sirtex Medical
First posted
Jan 27, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)

Conditions

  • Resectable Hepatocellular Carcinoma
  • Hepatocellular Carcinoma
  • Hepatocellular Cancer

Interventions

  • DurvalumabDrug

    Intravenous infusion

  • TremelimumabDrug

    Intravenous infusion

  • SIRTDevice

    SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: up to 18 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.